Article Text

Download PDFPDF
When is it too EARLY to start bosentan in pulmonary arterial hypertension?
  1. F Magdy
  1. Dr F Magdy, Junior Trainee in Cardiology, University Hospital of North Staffordshire, Stoke-on-Trent, UK; fmfouadissa{at}yahoo.co.uk

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Pulmonary arterial hypertension is a debilitating progressive disease which eventually leads to right heart failure and death. Although observational studies indicate that early treatment initiation might be advantageous, previous clinical trials only looked at the use of bosentan (dual endothelin receptor antagonist) in patients with advanced symptomatic states (WHO functional class III and IV).

The EARLY trial …

View Full Text